Rongjuan Wang
11 Papers
7 Citations
Rongjuan Wang is an academic researcher. The author has contributed to research in topics: Antibody & Neutralizing antibody. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Jinchao Zhang,Shuo Chen,Xun Gui,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor is reported.
Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
Mingzhu Wang,Junchao Wang,Rongjuan Wang,Shasha Jiao,Shuang Wang,Jinchao Zhang,Min Zhang +6 more
- 25 Oct 2019
TL;DR: It is shown that MW11-h317, an anti-PD-1 monoclonal antibody, displays high affinity for PD-1 and blocks PD- 1 interactions with PD-L1/L2.
Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
Rongjuan Wang,Chang Zhang,Yuting Cao,Junchao Wang,Shasha Jiao,Xiao Zhang,Min Wang,Peipei Tang,Zijun Ouyang,Wenlu Liang,Yuhui Mao,An Wang,Gang Li,Jin-chao Zhang,Mingzhu Wang,Shuang Wang,Xun Gui +16 more
TL;DR: Wang et al. as mentioned in this paper reported the development of a bispecific antibody 6MW3211 to block both PD-1/PD-L1 and CD47/SIRPα signals.
An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Shuo Chen,Xun Gui,Jinchao Zhang,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, is reported showing high SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor by introducing the LALA mutation to the Fc region (MW05/LALA).
7
Patent
Anti-human trop-2 antibody and application thereof
Shuang Wang,Rongjuan Wang,Shasha Jiao,Chang Zhang,Jiao Zhang,Dadi Zeng,Jinchao Zhang +6 more
- 15 Apr 2021
TL;DR: In this article, an antibody binding a human tumor-associated calcium signal sensor 2 (Trop-2) protein or fragments thereof, and use of the antibody or fragment thereof in preventing or treating diseases is described.